230 related articles for article (PubMed ID: 1320680)
1. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.
Welch SP; Stevens DL
J Pharmacol Exp Ther; 1992 Jul; 262(1):10-8. PubMed ID: 1320680
[TBL] [Abstract][Full Text] [Related]
2. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Welch SP; Thomas C; Patrick GS
J Pharmacol Exp Ther; 1995 Jan; 272(1):310-21. PubMed ID: 7815346
[TBL] [Abstract][Full Text] [Related]
3. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification.
Cichewicz DL; Martin ZL; Smith FL; Welch SP
J Pharmacol Exp Ther; 1999 May; 289(2):859-67. PubMed ID: 10215664
[TBL] [Abstract][Full Text] [Related]
4. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord.
Pugh G; Smith PB; Dombrowski DS; Welch SP
J Pharmacol Exp Ther; 1996 Nov; 279(2):608-16. PubMed ID: 8930163
[TBL] [Abstract][Full Text] [Related]
5. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice.
Welch SP
J Pharmacol Exp Ther; 1993 May; 265(2):633-40. PubMed ID: 8388455
[TBL] [Abstract][Full Text] [Related]
6. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
7. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.
Raffa RB; Friderichs E; Reimann W; Shank RP; Codd EE; Vaught JL
J Pharmacol Exp Ther; 1992 Jan; 260(1):275-85. PubMed ID: 1309873
[TBL] [Abstract][Full Text] [Related]
8. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
9. Spinal interactions between opioid and noradrenergic agonists in mice: multiplicativity involves delta and alpha-2 receptors.
Roerig SC; Lei S; Kitto K; Hylden JK; Wilcox GL
J Pharmacol Exp Ther; 1992 Jul; 262(1):365-74. PubMed ID: 1378095
[TBL] [Abstract][Full Text] [Related]
10. A characterization of the antinociception produced by intracerebroventricular injection of 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate in mice.
Welch SP; Dewey WL
J Pharmacol Exp Ther; 1986 Nov; 239(2):320-6. PubMed ID: 3095536
[TBL] [Abstract][Full Text] [Related]
11. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists: a common mechanism of action?
Welch SP; Dunlow LD
J Pharmacol Exp Ther; 1993 Oct; 267(1):390-9. PubMed ID: 8229767
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.
Vanderah TW; Bernstein RN; Yamamura HI; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1996 Jul; 278(1):212-9. PubMed ID: 8764354
[TBL] [Abstract][Full Text] [Related]
13. Intrathecal morphine and clonidine: antinociceptive tolerance and cross-tolerance and effects on blood pressure.
Solomon RE; Gebhart GF
J Pharmacol Exp Ther; 1988 May; 245(2):444-54. PubMed ID: 3367301
[TBL] [Abstract][Full Text] [Related]
14. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
Roerig SC; Fujimoto JM
J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
[TBL] [Abstract][Full Text] [Related]
15. Involvement of spinal kappa opioid receptors in the antinociception produced by intrathecally administered corticotropin-releasing factor in mice.
Song ZH; Takemori AE
J Pharmacol Exp Ther; 1990 Aug; 254(2):363-8. PubMed ID: 2166788
[TBL] [Abstract][Full Text] [Related]
16. The antinociception produced by intrathecal morphine, calcium, A23187, U50,488H, [D-Ala2, N-Me-Phe4, Gly-ol]enkephalin and [D-Pen2, D-Pen5]enkephalin after intrathecal administration of calcitonin gene-related peptide in mice.
Welch SP; Singha AK; Dewey WL
J Pharmacol Exp Ther; 1989 Oct; 251(1):1-8. PubMed ID: 2552070
[TBL] [Abstract][Full Text] [Related]
17. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
18. A proposed mechanism of action for the antinociceptive effect of intrathecally administered calcium in the mouse.
Welch SP; Stevens DL; Dewey WL
J Pharmacol Exp Ther; 1992 Jan; 260(1):117-27. PubMed ID: 1346158
[TBL] [Abstract][Full Text] [Related]
19. Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse.
Vaught JL; Mathiasen JR; Raffa RB
J Pharmacol Exp Ther; 1988 Apr; 245(1):13-6. PubMed ID: 2834533
[TBL] [Abstract][Full Text] [Related]
20. Modulation of morphine antinociception by swim-stress in the mouse: involvement of supraspinal opioid delta-2 receptors.
Vanderah TW; Wild KD; Takemori AE; Sultana M; Portoghese PS; Bowen WD; Hruby VJ; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1993 Oct; 267(1):449-55. PubMed ID: 8229774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
